Behind the science
AMR and the urgent need for novel antibiotics
The world desperately needs new antibiotics to get ahead of the growing threat of pathogens. However, the number of potential drugs in the pipeline has dwindled. Despite difficulties, some companies, including GSK, are pressing ahead, hoping to revive the field and take on one of the biggest health challenges facing humanity.
Our purpose
We are a focused biopharma company with strong momentum and big ambitions, to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive.Our R&D focus is on four therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases.
Behind the science
Discover how we're getting ahead
‘This could be a golden moment’: Is prevention the ‘medicine’ we need to end the HIV epidemic?
Remission could be possible for people with asthma, giving them a new outlook on life
‘We’ve seen an explosion in computing power’: Using AI, machine learning and data to unlock the mysteries of disease
‘Patients can breathe easier today’: Scientific advances in asthma and COPD care could prevent irreversible lung damage
Advanced technology is increasing the chances of improving outcomes for cancer patients
Robots, AI, and machine learning: how smart manufacturing is getting medicines and vaccines from factories to patients faster
Life at GSK
Find out what it's like to work with us
Make a difference with us
Do your best work with us
Be yourself with us
INVESTORS
We announced our full year and fourth quarter 2024 results on Wednesday 5 February
